CD40 binding antibodies and uses thereof
View Patent ↗An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
1. An isolated monoclonal antibody, or an antigen-binding portion thereof, binding to tumor necrosis factor receptor CD40, comprising a heavy chain variable region comprising a VH-CDR1 region, a VH-CDR2 region and a VH -CDR3 region, and a light chain variable region comprising a VL-CDR1 region, a VL-CDR2 region and a VL-CDR3 region, wherein the VH-CDR1 region, VH-CDR2 region, VH-CDR3 region and the VL-CDR1 region, VL-CDR2 region and VL-CDR3 region comprise amino acid sequences of SEQ ID NOs: 6, 13, 19, 25, 27 and 35, respectively.
2. The isolated monoclonal antibody, or the antigen-binding portion thereof, of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence set forth in SEQ ID NO: 43.
3. The isolated monoclonal antibody, or the antigen-binding portion thereof, of claim 1 , wherein the light chain variable region comprises an amino acid sequence set forth in SEQ ID NO: 57.
4. The isolated monoclonal antibody, or the antigen-binding portion thereof, of claim 1 , wherein the heavy chain variable region and the light chain variable region comprise amino acid sequences set forth in SEQ ID NOs: 43 and 57, respectively.
5. The isolated monoclonal antibody, or the antigen-binding portion thereof, of claim 1 , comprising a heavy chain constant region having an amino acid sequence set forth in SEQ ID NOs: 62, 63 or 64, linked to the heavy chain variable region, and a light chain constant region having an amino acid sequence set forth in SEQ ID NOs: 65 or 66, linked to the light chain variable region.
6. The isolated monoclonal antibody, or the antigen-binding portion thereof, of claim 1 , which (a) binds CD40, (b) binds monkey CD40; (c) does not bind to mouse CD40; (d) promotes CD40-CD40L interaction; (e) activates CD40 signaling; (f) promotes DC cell maturation; and/or (g) promotes CD4+ and/or CD8+ T cell proliferation.
7. The isolated monoclonal antibody, or the antigen-binding portion thereof, of claim 1 , which is a mouse, or chimeric antibody.
8. The isolated monoclonal antibody, or the antigen-binding portion thereof, of claim 1 , which is an IgG1, IgG2 or IgG4 isotype.
9. A pharmaceutical composition comprising the isolated monoclonal antibody, or the antigen-binding portion thereof, of claim 1 , and a pharmaceutically acceptable carrier.
10. A method for activating or inducing CD40 signaling to promote immune cell activation or proliferation in a subject having cancer, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 9 .
11. The method of claim 10 , wherein the cancer is a solid or non-solid tumor.
12. The method of claim 10 , wherein the cancer is selected from the group consisting of B cell lymphoma, chronic lymphocytic leukemia, multiple myeloma, melanoma, colon adenocarcinoma, pancreas cancer, colon cancer, gastric intestine cancer, prostate cancer, bladder cancer, kidney cancer, ovary cancer, cervix cancer, breast cancer, lung cancer, and nasopharynx cancer.
13. The method of claim 10 , further comprising administering an immunostimulatory antibody, a costimulatory antibody, a chemotherapeutic agent, and/or a cytokine.
14. The method of claim 13 , wherein the immunostimulatory antibody is selected from the group consisting of an anti-VISTA antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-LAG-3 antibody, an anti-TIM 3 antibody, an anti-STAT3 antibody, and an anti-ROR1 antibody.
15. The method of claim 13 , wherein the costimulatory antibody is an anti-CD137 antibody or an anti-GITR antibody.
16. The method of claim 13 , wherein the chemotherapeutic agent is epitubicin, oxaliplatin, and/or 5-fluorouracil.
17. The method of claim 13 , wherein the cytokine is GM-CSF and/or IL-4.